COVID-19 vaccines: GCC pharma investing billions across over 500 research projects

Pharmaceutical research companies and manufacturers across the Gulf region are sparing no efforts in tackling the COVID-19 challenges and are now investing billions of US dollars to produce vaccines and medicines.

At a recently held General Assembly in the UAE, members of the Pharmaceutical Research and Manufacturers Association in the Gulf (PHRMAG) committed to redouble their efforts to end the pandemic.

The association confirmed during the meeting that there are now more than 500 research projects devoted to developing a new generation of therapeutic and vaccines that will offer effective treatments, preventative or cures for the disease.

Several countries around the world are racing to produce COVID-19 cures and vaccines by next year.

So far, researchers in the UAE are undergoing Phase III clinical trials for its own vaccine, which has recently been approved for emergency use among frontline health workers.